Biogen to develop amyloid beta-targeting antibody platform
European Pharmaceutical Review
APRIL 12, 2023
Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ). The antibody transport platform The BBB protects the brain from harmful substances and pathogens circulating in the bloodstream. These include transferrin receptors, which are expressed at the BBB.
Let's personalize your content